New drug cocktail aims to shrink rectal tumors before surgery

NCT ID NCT06884670

Recruiting now Disease control Sponsor: The First Affiliated Hospital with Nanjing Medical University Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 14, 2026 · Updated 25 times

Summary

This study tests whether giving a mix of immunotherapy (PD-1 blocker and IL-2) plus chemotherapy before surgery can shrink tumors more effectively in people with locally advanced rectal cancer. About 130 adults with a specific type of rectal cancer (MSS/pMMR) will take part. The goal is to see if this approach leads to higher rates of tumor shrinkage or complete disappearance before surgery.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Jiangsu province hospital
RECRUITING

Nanjing, Jiangsu, 210029, China

Contact Phone: •••-•••-•••• Email: •••••@•••••
Nanjing BenQ Hospital
RECRUITING

Nanjing, Jiangsu, 210000, China

Contact Phone: •••-•••-•••• Email: •••••@•••••
The Affiliated Hospital of Jiangsu University
RECRUITING

Zhenjiang, Jiangsu, China

Contact Phone: •••-•••-•••• Email: •••••@•••••
Xuzhou Central hospital
RECRUITING

Xuzhou, Jiangsu, China

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

RECTAL CANCER